Hemab raises $55M to target multiple rare bleeding indications

Hemab has raised $55 million to advance a pipeline of bispecific and monoclonal antibodies to treat patients with rare bleeding disorders. The series A round equips Hemab to take its lead program to clinical proof of concept while advancing its vision of becoming a hemostasis and thrombosis leader.